WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 7.523
Volume 6, Issue 4, 611-631. Review Article ISSN 2277– 7105

# RECENT REVIEW ON NANOFIBER FOR DRUG DELIVERY SYSTEMS

**Amandeep Singh*[1] and Narinder Singh[2]**

[1]Department of Pharmaceutics, Bahra Group of Pharmacy, Patiala, Punjab.

[2]Department of Pharmaceutics, CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar, Punjab.

Article Received on
31 Jan. 2017,

Revised on 20 Feb. 2017,
Accepted on 13 March 2017

DOI: 10.20959/wjpr20174-8190

***Corresponding Author**
**Prof. Amandeep Singh**
Department of Pharmaceutics, Bahra Group of Pharmacy, Patiala, Punjab.

## ABSTRACT

Electrospun nonwoven nanofibers are rising as a novel dosage form for multipurpose treatment adjacent to sexually transmitted infections, including HSV, Controlled release systems have beneficial for the health management, release of formulation for life science application and tissue engineering scaffolds. Nonwoven structures are used widely in health system because of their great surface area; many more properties are process cost effectiveness, absorbable, simplistic processing. For water loving small molecule drugs, their high water solubility and poor partition and uneven compatibility with mysterious polymers make it long term release yet more challenging. At this point explore several strategy to continue release of water loving small molecule drugs that are highly loaded in electrospun fibres. Various drug-incorporation techniques with the help of electrospinning like blending, co-axial electrospinning. Types of polymers used in sustained release of drug and effect of polymer on drug release. Strategy for sustained drug release from electrospun fibres and their release mechanism.

**KEYWORDS:** Nanofiber, Drug release mechanism, Technique, Application.

## INTRODUCTION

Nanofabrics are compiled of nonwoven nanofiber. Those are created by a process called electro spinning. This is a major way to persuade (without self-assembly) nanostructures that differ in: Fiber Diameter, Mesh Size, Porosity, Texture, Pattern arrangement Grafts: Woven vs. Nonwoven. The nonwoven structure has distinctive features: Interconnected pores, great surface-to-volume ratio, facilitate Nano fibrous scaffolds to have many biomedical and

industrialized applications. Fibers are irradiated with UV light through spinning in order to form cross linked graft scaffolds. During drug liberate kinetics, biodegradability and mechanical properties can be controlled by careful selection of polymers and electrospinning processing factors while biocompatibility of electro spun mats may be improved during surface modification of the nanofibers.[1] Electrospinning is an well-known method to produce small diameter fibers in the range of nanometres to a number of micrometres. Considering as the advent of using electrostatic force to produce electrospun in the 1930s [2] the procedure of electrospinning has become widely used in many engineering fields as well as filtration[3] masking/textile, sensors and energy-associated applications.[4] The theory of electrospinning, which comprise the role of processing variable, solution variables, structural design and mechanical properties, has been widely reviewed by others in the past.[5] Adding together, there have been a number of comprehensive reviews on scale-up development for electrospinning and their purpose in tissue engineering and drug delivery.[6, 7] Along with the biomedical applications, Delivery of drug is one of the most capable areas to employ electrospun materials. The advantages of using electrospun fibers in drug delivery consist of: (1) Drug loading is high (up to 60%) and encapsulation effectiveness (up to 100%), (2) polymers range to accommodate compatibility with physicochemical different agents (3) capability to adjust drug release[8] and (4) process easiness and cost-effectiveness. Because of the proposal versatility of electrospinning, there is an capable interest to distinguish the role of electrospun materials arrangement with clinical gaps related with cure and prevention of bacterial and viral infections. The advance of long acting drug formulations is being required in many of these applications to overcome challenges with adherence and emerging drug resistance. However, lots of antimicrobial agents require high and frequent dosing for efficiency due to their low intrinsic potency and half-live is short, when given *in vivo.*[9] For illustration, some common antibiotics used for treatment of bacterial infections are classically dosed at a minimum of hundreds of milligrams per days to weeks. Long-acting approach for HIV prevention and treatment need similar dosing treatment for existing antiretroviral drugs presently on the market.[10] The more aqueous solubility of several lead antimicrobial agents further exclude their formulation into long-acting dosage forms by model techniques such as grind to produce nano-sized crystalline drugs. A better consider rate of the recent design space necessary to achieve sustained release from electrospun fibers will help in form the platform's applicability to address these specific clinical gaps in drug delivery.[11] We give specific attention to move towards for sustaining the release of water loving small molecule drugs that are extremely loaded in fiber. In particular, we attention on

example of drug-eluting fibers that meet a minimum of 20 wt% loading and attain at least daily release of 10 to100 milligrams of drugs for up to a week or longed. The research and advance in the field has engaged uniaxial fibers or core-shell fibers that fabricated by coaxial electrospinning[12], which will be the major prominence of this review. These study highlight our recent knowledge of the material composition and solid-state characteristics needed to attain high dosing and sustained release of agents from electrospun fibers in applications involve long-acting clinical efficacy[11] Nanofiber drug delivery systems are capable to improve therapeutic efficacy, diminish toxicity, and can be designed to control and prolong drug release by regulate the degradation rate of the polymer.[13] Poly vinyl alcohol (PVA) is a able to degradable within the body, hydrophilic polymer with different properties for example more degree of swelling, intrinsic non-toxicity and good biocompatibility.[14] Aliphatic polyesters like poly (D,L-lactide) (PLA) and its copolymers with glycolic acid (PLGA) are biodegradable and biocompatible polymers with extremely broad applications in sustained drug delivery Cyclodextrins (CDs) belongs to group of cyclic oligosaccharides. They are capable to form inclusion complexes with lipophilic molecules which have been exposed to improve, dissolution rate and aqueous solubility as well as rate and extent of drug to reach in to the systemic circulation of lipophilic drugs without declining the intrinsic ability of the lipophilic drug molecule to enter in the biological membranes(Szejtli 1997). Customized CDs, such as at random methylated b -cyclodextrin (RM b -CD) have expand increasing popularity due to its enhanced water solubility and less toxicity than the natural b -cyclodextrin. To adjust the release of drugs from a drug delivery system and altering the release kinetics over a period of time by use blends of hydrophilic and hydrophobic polymers. The electro spun nonwoven nanostructure(a) has interrelated pores, (b) with pore sizes of the instruct fiber from few times to a few ten times the fiber diameter, and (c) the pore space to material ratio is on the order of 3:1 or still higher. The mixture of these three features involve a privileged permeability (due to the great pore volume) that can tolerate up fouling better and smaller pore sizes, linking that the electro spun nonwoven nanostructure can carry yet thinner coatings that are liable for the definite fluid filtration.[1]

**The advantages of an Electrospun**

Scaffolds have a tremendously high (favourable) surface-to-volume ratio, suitable porosity, and malleability to conform to a wide selection of sizes, textures and shapes. Additionally, scaffold composition and production can be controlled to provide a specific desired properties and functionality. Nanofiber structure and morphology can also be altered after production to

closely match with the native tissues, to mimic native physiological environment at, for example, an injury site.[1] The utilization of electrospun scaffold while cell delivery vehicle has been considerably bigger in recent years due, in part, to the physical similarity in between the Nano fibrous scaffolds and the extracellular matrix (ECM) originate in the native tissues.[15] The inherent architecture of electrospun scaffolds provides a favourable substrate to more accurately assess cellular behaviour in vitro. Furthermore, while other well-known manufacturing techniques have been utilized to thoroughly investigate their efficiency in fabricate viable cell scaffolds[16], electro spinning affords the ability to precisely manage a vast array of limitation in tailoring the nanofiber scaffold for precise biomedical applications ranging from prevent postoperative adhesions to the inspiring tissue regeneration. outside the various array of synthetic polymers that are utilize as primary element of electrospun scaffolds some researcher have motivated regarding replace the comparatively inexpensive synthetic polymers for naturally going on polymers that stay alive in the human body to more replicate the inhabitant environment of the host tissue. Therefore, the scaffold would be construct with the major protein(s) that are available in the ECM. For exemplar, poly (amino acid) [poly (aspartic acid)] have been explore into helping as a bioactive moiety in polymeric scaffold.[17] On behalf of these scaffolds, the existence of the poly (aspartic acid) was useful for cell proliferation, osteoblast adhesion, plus differentiation subsequent seven days. One more example is collagen nanofibers; both type I and type III collagen are the predominant structural elements of the ECM in some tissues. The fibers closely seem like the natural dimensions and structural design of collagen fibrils assembly up the ECM and bear cell growth and penetration within the scaffold[18] the properties of characteristic electrospun polymeric nanofibers consequence from the shear forces to which they are focus during the quick electrospinning method and from the small fiber diameter. The great SDR exert by the electrostatic fiber stretch procedure frequently results in a very good molecular arrangement, as evidence in the very high degree of favoured direction in wide-angle X-ray diffraction (WAXD) dimensions for) the example of electrospun poly(l-lactic acid) (PLLA) nanofiber.[5] However, the degree of crystallinity may be comparatively low in vision of the very small fiber diameter as well as the very little transit time existing for the crystal formation. yet, one would expect that the good molecular arrangement (envisioned while an oriented mesosphere) might also lead to a higher tensile strength as compared to the microfiber case, but there have been reports that this is not available in the case[19] most probably due to imperfections and pores within the nanofibers. Various technique differential-thermal measurements (DSC) as well as WAXD indicated that the crystalline of PLLA nanofibers

was deprived compare to that of bulk PLLA[1], mainly due to the rapid evaporation and solidification process through electrospinning, as in brief discuss above. DSC as well show a shift in the glass transition temperature of PLLA nanofibers to lesser values when evaluate with that of bulk PLLA, perhaps as a outcome of the very large specific exterior of the nanofibers, the enclosure of plasticizers in addition to air itself and/or an increase in the segmental movement of those polymers chains close to the exterior. The exterior of nanofibers is frequently structured with pores, additional increasing the already high surface-to-volume ratio.[20]

## DRUG-INCORPORATION TECHNIQUES VIA ELECTROSPINNING

Therapeutic agents and drug incorporated into electrospun nanofibers through various techniques like blend electrospinning, chemical immobilization, co-axial electrospinning, physical adsorption and emulsion electrospinning (Scheme 1). There are four likely approaches of the drug in the resulting nanostructured materials[21] the drug may be envoy as particles to the surface of the polymer which is in the form of nanofibers or both the drug and the polymer are nanofiber-form, resulting in an end product whereby two kinds of nanofibers are interlaced together. Another prospect is that the blend of the drug and the polymer are integrated into one type of fiber containing both components. Ultimately, the polymer is electrospun into a tubular shape in which the particles of drug are encapsulated.

### Blending

The most universal technique of drug merging is the blending process in which the drug is dissolved in a polymer solution and the resultant solution electrospun to fabricate drug loaded electrospun nanofibers. For design calculation of diclofenac sodium in the path of a explanation of48 N-butyl hemiester of poly(maleic anhydride-alt-2-methoxyethylvinylether) in acetic acid modify the electrical conductivity of the solution, in which it turn caused a lessen in fiber diameters 49 On the another way an increase in fiber diameter was noted with adding upon meloxicam to PVA due to rise in solution viscosity.[21] Blending is a fairly simple procedure compared to other encapsulation ways such as emulsion or co-axial electrospinning. Though, a number of needs have to be met in order to attain the required results in expressions of drug release. For example, the drug molecules have to be consistently spread in the fibers and not situated on the fiber surface. As exposed by the SEM images in Figure 1, both exterior and cross-section showed comparatively homogeneous drug distribution inside the electrospun fiber[23] The amount of drug included within the

electrospun fibers can be resolute through UV-Vis spectrophotometry analysis and their chemical veracity can be confirmed by 1H-NMR51. Furthermore, the structural constancy may also be determined by means of reverse phase HPLC as shown in a study.[23] The authors also utilized X-ray diffraction to inspect the crystalline circumstances of drug in the electrospun nanofibers. They detailed that pure hydroxycamptothecin (HCPT), which is crystalline with main peaks at 2θ= 11.5° and 13.5°, was included in the amorphous state in poly (DL-lactic acid)-poly(ethylene glycol) (PELA) nanofibers. This was description for by competent solvent evaporation) which gave the incorporated drug partial time to recrystallize.[24] In totalling, DSC analysis of drug-loaded electrospun nanofibers is often carry out to explore the result of the drug on polymer chain mobility. Certainly, the occurrence of small drug molecules can be able to act on the molecular chains and make the later move easily, leading to a reduce in the glass transition temperature (Tg). The physicochemical possessions of polymers as well as their contact with drug molecules have to be regard as they affect drug encapsulation efficiency, drug delivery and drug release kinetics. To attain perfect encapsulation of the drug within the electrospun fibers, the hydrophobic-hydrophilic belongings of the polymer and the drug should be corresponding in other phrases, lipophilic drugs for example rifampicin and paclitaxel and hydrophilic ones such as doxorubicin hydrochloride should be loaded with lipophilic and hydrophilic polymers correspondingly. Drug and polymer inappropriateness marks in the drug molecules migrating to the fiber texture fiber surface, leading to a explode release.[26] To inculcate achieve sustained release, electrospinning of hydrophilic-hydrophobic polymer blends have been conceded out by many Researchers. Results illustrated that drug loading efficiency might be enhanced and burst effect reduced through the adding together of hydrophilic polymers such as gelation, PEG or PVA.[27]

**Surface alteration-chemical immobilization**

Bio functionality can be initiated into electrospun Nano fibrous mats by surface modification with target biomolecules. Surface modification of nanofibers consists of plasma treatment, wet chemical method along with surface graft polymerization[28] Owing to the processing advances of synthetic polymers, a wide variety of molecules having distinctive biological functions be capable to immobilized onto the Nano fibrous surface not including compromising bulk properties. The healing agent is chemically bound otherwise conjugated to the fiber surface, thereby persist its functionality and falling burst effect[29] Primary carboxylate groups and amine are mainly wide-range used to immobilize bioactive molecules

taking place the surface of nanofibers. Chemical immobilization not only decrease release rate of the target biomolecule drastically however also allows its precise control 16 via beginning of responsive materials to local external cues.[30] It is consequently more appropriate for gene or growth-factor release where a slow and long-lasting delivery is required 63-67. though, drugs that are involve to be endocytosis or that require interaction through the cell nucleus cannot be immobilized in this means[31] Polymer substrates plasma treatment have been used to tailor surface adhesion and wetting properties by modify the surface chemical compositions suitable choice of the plasma source permits the introduction of diverse functional groups with the target surface which, in twist allows subsequent covalent immobilization of bioactive molecules. For example, carboxyl or amine groups on nanofiber surfaces could be generated through typical plasma treatments through oxygen, ammonia or air[32] new efficient groups can also be created using partial surface hydrolysis through wet chemical process. This way is based on the casual chemical scission of the ester linkages intriguing place the polymer backbones situated on the surface of the nanofibers, ensuing in the generation of hydroxyl or carboxylic groups. although, special concerned taken attention the duration of the hydrolysis and the concentration of the hydrolysing agent to most suitable produce surface functional groups with no changing the bulk properties drastically[34] graft polymerization has been subjugated not only to confer exterior hydrophobicity but in adding together to introduce multi-functional groups on the surface intended for covalent immobilization of bioactive molecules.[35]

**Co-axial electrospinning**

This is a customized edition of electrospinning which approve the fabrication of fibers by core– shell morphology. This process is mainly used to include of biomolecules for example growth factors and DNA which form the inner core of the productant electrospun fiber. The core-shell structural designs stay the core ingredient from throughout introduction to the biological environment and tender to the sustained and long-lasting release of the therapeutic agent.[30] The main benefit of this way over the frequently used electrospinning is that the fibers are made-up from two divide solutions. This reduces the interaction among aqueous-based organic molecules and the crude solvents in which the polymer is typically dissolved. As the outcome, the bioactivity of uneven biological molecules can be protected.[35] It has been shown so as to the growth factors liberated from these co-axial fibers had the similar level of bioactivity as a fresh growth factors. A variety of factor, such as shell polymer concentration, concentration of core polymer, molecular weight and drug concentration

decides the promising encapsulation of the drug in the core of the co-electrospun fibers. in addition, the encapsulation effectiveness of the drug is affected by the comparative flow rate of the core and shell solutions[36] though co-axial electrospun nanofibers develop huge interest as gene- and growth factor-delivery arrangement, other kind of therapeutic agents, for example antibiotics, antioxidant drugs or steroids have been filled into co-axially electrospun nanofibers for different applications.[37] For example, He et al. declaration on the fabrication of tetracycline loaded poly(L-lactic acid) (PLA) nanofibers by the use of coaxial electrospinning. They illustrate that fiber diameters might be controlled by adjust the concentration of the shell solution which, in turn influenced the release activities. Besides formulated resveratrol and gentamycin sulphate loaded PCL nanofibers. Sustained release behaviour with no burst outcome was reported since the drug has ample diffusional paths. Adding together, this procedure does not require good interaction among the polymer and the drug but it have sufficient interfacial compatibility to avoid delamination[38] Recently Generated a novel dual drug delivery system in which the drugs were separately loaded in each the casing or the core of the fiber. The tri-axial fiber mat permitted both a rapid release from the outer case layer for short-term treatment and a sustained release from the fiber core for lasting treatment. The middle layer between inner core and outer casing acts as a barrier to avoid leaching from the core, which can be essential when the mats are used in wet application.

**Physical Adsorption**

Physical surface adsorption is the easiest approach for drug inclusion into electrospun nanofibers. The dynamic force for surface adsorption is usually electrostatic interface, hydrogen bonding, lipophilic interaction and Van der Waals interaction.[39] Several studies have exploited the use of the specific interaction between heparin and growth factors .Heparin is a greatly sulphated glycosaminoglycan and is well-known to have a strong binding sympathy with various growth aspects for example fibroblast growth factor and vascular endothelial growth and another factor heparin-binding epidermal growth factor (HBEGF) and transforming growth factor-β (TGF-β), the most well-organized approach for local delivery of growth factors is via immobilization of heparin on the biomaterial exterior followed by succeeding attachment of growth factors[40] produced an electrospun heparin-conjugated poly(ε-caprolactone) mat to expand a functional scaffold for the manage release of VEGF.19 VEGF immobilization was attained throughout affinity binding between heparin and VEGF molecules. Bioactivity of VEGF was ensured by endothelial cell adhesion and

proliferation assays.[42] From the scaffold sustained release of VEGF for up to 15 days was observed. Also, exhibited the sustained release of platelet obtained growth factors (PDGFs) from an electrospun PCL/gelation scaffold which can be controlled by conjugating molecules of heparin to the fibers.

**Emulsion electrospinning**

In the process of emulsion electrospinning, aqueous protein solution or drug is emulsified inside a polymer solution (oil phase) and following electrospinning, the biomolecule-loaded phase be capable of distributed within the fibers if a low-molecular-weight(LMW) drug is used or form a core–shell fibrous configuration when small molecules are integrated in the aqueous phase. Emulsion electrospinning removes the need for a ordinary solvent accordingly, various drugs having hydrophilic nature and hydrophobic polymeric combinations can be applied. Furthermore, the drug contact with organic solvent is minimum through this procedure.[42] But, compare to co-axial electrospinning, emulsion electrospinning can cause degradation of unstable small molecules like plasmid DNA (pDNA), perhaps due to shearing force or interface tension within the organic phases and aqueous phase of the emulsion. One more disadvantage of emulsion electrospinning is that emulsification and ultra-sonication procedures increase the probability of protein degradation it leads to damage of protein.

## MATERIAL COMPOSITION FOR SUSTAINED DRUG RELEASE FROM ELECTROSPUN FIBERS

**Polymers and excipients**

The selection of polymer represents a mean component in the progress of sustained release electrospun fibres. The seemingly infinite number of natural and synthetic polymers that might be electrospun places of attention the versatility of this platform. Subsequently, the intended application of sustained release fibres often dictates polymer preference. In both cases non-biodegradable and biodegradable polymers have been utilized for sustained release from electrospun fibres.[43] The most widespread polymers make use of electrospun fibers for sustained release are biodegradable polyesters name as PLA(Poly lactic acid), one more polyglycolic acid (PGA), poly lactic-co-glycolic acid (PLGA) and polycaprolactone (PCL) polymer common non-degradable synthetic polymers create use for sustained drug release comprised of polyurethane (PU), polycarbonate and nylon expressed controlled release of two hydrophobic drugs loading at 10-40 wt% in PU electrospun scaffolds.[44] While a number

of naturally taking place polymers such as silk, collagen, gelatin and one more alginate and chitosan have been explore for sustained drug release effect from fibers, their shear-thinning property construct them difficult to electrospin alone or at high yield. These polymers have been re-examining by[45] on their capability to electrospin into nanofibers. The means of drug release from fibers with this polymeric composition can be credited to a mixture of diffusive processes|, polymer decomposition, drug partitioning in polymers and dissolution of drug. The polymer having degradable and non-degradable polymer are also non-swell able, drugs take in to diffuse through the solid polymer matrix prior to diffusion into the bulk. Drug diffusion rate from the polymer matrix reproduces a number of processes as well as the rate of water diffusion into the polymer, solubility and partitioning of the drug linking the polymer and the bulk and diffusivity of the drug in the polymer. In non-degradable polymers, the normal distance a drug diffuses throughout the polymer matrix is dependent on the fixed geometry. In distinction, the geometry meant for a biodegradable polymer changes by time and the average distance of diffusion will differ depends on the pace of polymer degradation. Semi-crystalline and glassy polymers are often used for sustained drug release because of the slower rate of water diffusion within these materials. Cross-linked polymers be able to hinder water penetration, which construct them useful materials for a number of sustained release application[46] established that controlling the Lipophilicity of PCL fibers by a dopant is an efficient strategy to tune drug release by moving the rate of water dispersion into the electrospun porous fiber complex. In contrast, other excipients such as glycerol have been used to improve the wetting process and get faster drug release.

**Hydrophilic agents for sustained release**

Although a wide diversity of agents can be integrated into electrospun fibers most examples of sustained release drug come out to at least 7 days have been mainly limited to hydrophobic tiny molecule drugs or huge biological macromolecules. These agent are additional amenable to sustained release owed to their meagre solubility, large size, or favoured partition into insoluble polymers. In dissimilarity, hydrophilic small molecule drugs represent a major difficult aspect in sustained release because of high solubility with release media, reduced partitioning and small compatibility with many hydrophobic polymers. Drug-polymer compatibility correlates strongly with the capability to fully encapsulate drugs and achieve sustained release. Hydrophilic small molecules tend to have low solubility with hydrophobic solvent-polymer systems. In these situations, the hydrophilic molecules are inherently more probable to partition to the exterior of fibers. A majority of the studies investigate hydrophilic

small molecule drug load and release from electrospun fibers have persistent on antibiotics and some antiviral compounds.[47] The physico-chemical variety of tiny molecule drugs with respect to parameters such as water soluble, partition coefficient, pKa, ionization and molecular dipole, glass transition and melt temperature, are all important factors that will contribute to its interaction with the solvent and polymer both in solution and in the final solid dispersion. by itself, using model water soluble compounds to extrapolate structure-function relationships between the fiber formulation kind and drug discharge kinetics should be interpreted with caution. For example, a recent study by(Carson, Jiang et al. 2016) established the capability to tune the release 10-40 wt% tenofovir from 24 hours out to 30 days, using PCL/PLGA fibers. The study show that higher PCL or PLGA content yielded faster or slower diffusional release of tenofovir, correspondingly. The objective was to generalize the PCL/PLGA electrospun fiber platform to other water soluble tiny molecule drugs. Though, the release of azidothymidine, maraviroc, raltegravir and tenofovir disoproxil fumarate was a great faster compare to tenovir, using equivalent PCL/PLGA fiber formulations.[11] This suggests that yet slight differences inside the chemical structures of these compounds, compared to tenofovir, can affect rate of release. It appears that the presence of a phosphoric acid functional group on tenofovir creates a unique interaction with PCL/PLGA polymer backbones and inhibits release. Therefore, a deeper understanding of the drug-polymer-solvent interactions at all stages of the electrospinning procedure will need availability and access to lead clinical compounds.

**Effect of polymer and drug dispersion on sustained release**

In contrast to burst release fibers, sustained release fibers require wide design thought depend on the desired drug release application. Because burst release fibers usually fit in fast dissolving polymers, which quickly hydrate in aqueous solution and dump their drug load[48] aim of these systems are comparatively simple when compare to design constraints necessary for sustained release applications. Briefly, major propose elements may include polymer choice, drug physiochemical properties, drug-polymer compatibility, property of formulation, and limitation involves in electrospinning procedure. The interplay of each aforementioned design parameters can significantly influence the release profile of drug loaded-electrospun fiber. The mechanisms of sustained release from electrospun fibers can be complex. However, the rate of matrix hydration and drug diffusion out of polymer has been the primary focus of many studies in this section, discuss how each of these aspects contributes to the design of sustained release uniaxial electrospun fibers. Examples of sustained release curves

from electrospun uniaxial fiber: (a) 10 wt% loaded paclitaxel drug in PLGA microfibers (PLGA MF) and nanofibers (PLGA NF) and first order release arc fitting for microfiber (MF) (k = 0.119, n = 0.45) and nanofibers (NF) (k = 0.223, n = 0.45).Release of paclitaxel constant for 60 days to 80% cumulative liberate in PLGA NF and 60% cumulative release in PLGA MF. Fiber diameter considerably influence the release profile (b) Release curves of SN-38, a bioactive agent, from blends of PCL and (PGC-C18) poly(glycerol monostearate-co-ε-caprolactone) at ratios of 90:10, 70:30, 50:50 PCL:PGC-C18. Effect of air displacement was least for the degassed 90:10 PCL:PGC-C18 mesh comparing to the native one. Melted mesh (at 80°C for 1 min) reduces the pores and more eliminated time required for air displacement comparing to the native one. Higher PGC-C18 doping in the mesh drastically reduce the release rate. The effect on air displace has a direct influence on the wetting of the mesh and thus affects the release rate.[11] As mention earlier, PLGA is a well-known electrospun fiber system for sustained release of water soluble and lipid soluble compounds. the sustained release of anti-cancer drug paclitaxel, a lipophilic drug, not in to 60 days from PLGA electrospun fiber load at 10 wt%. The identical PLGA fiber used by. Confirmed controlled release of cefoxitin sodium salt, a water soluble antibacterial drug integrated at 5 wt%. While, in this study the conclusion showed that 1 wt% and 5 wt% loaded cefoxitin sodium salt results in a chief burst portion within the first hour in release from PLGA fibers. Incorporation of PLA/PEG-b-PLA into PLGA give up constant sustained release of 27% of loaded drug above one week, following an initial burst phase. These examples confirm the use of PLGA for long-term discharge of a hydrophilic drug out to two months and sustain release of a hydrophobic drug out to one week. While, important gaps in sustained release remain, mainly associated to the sustained release of hydrophilic molecules. The revise by[49] still shows major burst release (~50-70% in first hour) and at 5 wt%, the loading is still low as compared to what would be needed for many clinical appliance, which need high doses and practical total dosage sizes. Established that the use of superhydrophic electrospuno fibers could control air-displacement and sustain release of a 1 wt% small molecule hydrophobic drug past 60 days. This study focused on controlling the rate of matrix hydration as a means of sustaining drug release. In this study, the mechanism of drug release relied on the accessibility of drug in polymer to media. The high glass transition temperatures of polymers such as PLGA provide a different mechanism of sustained release, on a molecular level, by inhibiting drug diffusion through polymer chains. This mechanism hinges on the dispersal of drug molecules through polymer networks within single electrospun fibers.[11] showed the effect of polymer Tg on drug release. In the study, hydrophobic dexamethasone

was loaded at 10 wt% into two polyurethanes with low and high glass transition temperatures. The results showed that diffusional drug release was much slower for the high Tg polyurethane and much fasterin the low Tg polyurethane. Furthermore, blends of the two polymers yielded Intermediate release of the hydrophobic drug. The examples above incorporating hydrophobic drugs into fibers showed sufficient sustained release but again are limited by the relatively low drug loading used in the fibers. An important the thickness and composition of the shell in coaxial fibers play important roles since both affect how well the drug is encapsulated in the core and the wetting behaviour of the coaxial fibers during release.[50] used hydrophobic PLA and poly(3-hydroxy butyrate) (PHB) to produce coaxial fibers loaded with dimethyloxalylglycine(DMOG).They observed that coaxial fibers made of PHB-core and PLA-shell exhibited a burst release whereas those made of PLA-core and PHB shell exhibited a two-phase sustained release over 30 days. The first phase of the release was shown to be independent of the shell thickness. However, the second phase showed a linear release that was sustained over 30 days and was dependent on the shell thickness. For example, thin shells (~120 nm) showed ~70% cumulative drug release in 11 days, whereas thick shell (~230 nm) required >30 days to reach the same cumulative percent release. In this example, sustained release of hydrophilic small molecules from coaxial fibers strongly depends on the hydrophobicity of the shell layer and the thickness of the shell. (Llorens, Ibañez et al. 2015) compared the release of triclosan (an antibacterial drug) and curcumin (an anti-carcinogenic drug) loaded in the core of coaxial fibers made from PEG and poly (butylene succinate). Their results showed that drug release was higher from poly (butylene succinate)-core and PEG-shell fibers than core-shell fibers of the opposite composition. In addition, they observed that drug releases from core-shellfibers were associated with a controlled wetting mechanism.

**Table No. 1 Strategies for sustained drug release from electrospun fibers**

| Type of polymer | | PLGA | | PLA | | | PLLA | |
|---|---|---|---|---|---|---|---|---|
| Unaixial fiber | Factor | Paclitaxil | Cefoxitin Sodium | Tetracycline Hydrochloride | Metronidazole | Amoxicillin | Paclitacel | Doxorubicin hydrochloride |
| | Loading wt % | 10 | 5 | 5 | 40 | 7 | 15 | 1.6 |
| | Aq/soln Mg/ml | <0.01 | 0.15 | 0.46 | 29 | 0.58 | <0.01 | 1.18 |
| | Log pa | 3.95 | -0.92 | -0.42 | -0.14 | 0.88 | 3.95 | 1.41 |
| | 1 hr | 10% | 70% | 35% | 5% | 10% | 0-1% | 70% |
| | 24 hr | 22% | 72% | 35% | 25% | 15% | 0-1% | 87% |
| | 72 hr | 40% | 80 | 35 | 45% | 20% | _ | _ |

**Table No. 2 Strategies for sustained drug release from electrospun fibers**

| Type of polymer | | PLLA | Polyurethane | Polyurethane | | | PEG:PBS 3/1 | 28%Zein:1% Zein 4/1 |
|---|---|---|---|---|---|---|---|---|
| Unaixial fiber | Factor | Doxirubicin | Itraconazole | Ketanserin | Coaxial fibers (core:shell Qc/QS | Triclosan | Curcumin | Ketoprofen |
| | Loading wt % | 1.6 | 40 | 10 | | 5 | 5 | 10 |
| | Aq/soln Mg/ml | 0.41 | <0.01 | <0.01 | | <0.01 | 0.05 | 58 |
| | Log pa | 0.24 | 4.99 | 3.56 | | 5.34 | 3.07 | 2.91 |
| | 1 hr | 20% | 2ug/cm | 2ug/cm | | 75% | 90% | 5% |
| | 24 hr | 20% | 20ug/cm | 10ug/cm | | _ | _ | 100% |
| | 72 hr | _ | _ | _ | | _ | _ | _ |

**Table No. 3 Strategies for sustained drug release from electrospun fibers**

| **Type of polymer** | | **PCL:Gelatin ½** | **PCL:PVA 1/8** | **PLLA:PVA 1/8** | **PLGA:PVA 1/8** | **PLGA:PVA 1/8** | **PEG:PLA ¼** | **PEG:cellulose acetate and gelatine ½** | **PMMA:Nylon6 1/1** |
|---|---|---|---|---|---|---|---|---|---|
| Unaixial fiber | Factor | Metronidazole | Metroclopramide hydrochloride | Metroclopramide hydrochloride | Metroclopramide hydrochloride | Salicyclic acid | Salicyclic acid | Amoxicillin | Ampicillin |
| | Loading wt % | 33.4 | 1 | 1 | 1 | 10 | 10 | 3.7 | 20 |
| | Aq/soln Mg/ml | 29 | 0.24 | 0.24 | 0.24 | 1000 | | 0.58 | 0.87 |
| | Log pa | -0.14 | 2.36 | 2.36 | 2.36 | 2.01 | | 0.88 | 1.48 |
| | 1 hr | 5% | 2% | 5% | 5% | 10% | | 22% | 100ug/ml |
| | 24 hr | 60% | 55% | 38% | 38% | 25% | | 100% | 300mg/ml |
| | 72 hr | 95% | 65 | 62% | 62% | 40% | | _ | 600ug/ml |

**Table No. 4 Drug release with their release mechanism**

| Polymer | Drug loading (% by weight) | Release mechanism | Studied release time |
|---|---|---|---|
| PCL[51] | Heparin (0.05,0.5) | Bulk diffusion | 14 days |
| PCL[52] | Metronidazole benzoate (5,10,15) | Bulk diffusion | 20 days |
| PDLLA[53] | Paracetamol (2,5,8) | Bulk diffusion, Hydrolytic degradation | 350 hours |
| PCL,PLA[54] | Tetracycline (2) Chlorotetracycline Hydrochloride Amphotericin | Bulk diffusion | 1.5 hours |
| PCL-co-EEP[55] | NGF(0.0123),FITC-BSA(4.08) | Bulk diffusion | 90 days |
| PLGA[56] | Paclitaxel(9.1) | Bulk diffusion, hydrolytic degradation | 80 days |
| PDLLA[57] | Tetracycline (2) chlorotetracycline(2) | Bulk diffusion, polymer swelling | 50 hours |
| PU[44] | Itraconazole (10,40) Ketanserin(10) | Biphasic diffusion | 20 days |
| PVA[58] | Sodium salicylate(10,20) diclofenac sodium (10,20) naproxen (10,20) indomethacin (10,20) | Bulk diffusion, polymer erosion | 24 hours |
| PVP[59] | Ibuprofen (20,33.3) | Polymer erosion | 180 seconds |

**Application of Nanofibers**




## CONCLUSION

This revise investigated application and advantages of electrospun nanofibers in various fields. Benefits of electrospinning high drug loading, entrapment efficiency, in process sterilization of formulation. In case of conventional formulation they show burst release of drug random doses should be required to attain the therapeutic level. With the help of various

polymers and electrospinning method we can design the drug release within their mechanism. The frequency of dosing is reduced by control the release of drug.

**REFERENCES**

1. Burger C, Hsiao BS et al. Nanofibrous materials and their applications.Annu. Rev. Mater. Res. 2006; 36: 333-368.
2. Maretschek S,Greiner A et al. Electrospun biodegradable nanofiber nonwovens for controlled release of proteins. Journal of Controlled Release. 2008; 127(2): 180-187.
3. Singh S, Webster DC et al. Thermosensitive polymers: synthesis, characterization and delivery of proteins. Int j of pharmaceutics. 2007; 341(1): 68-77.
4. Tekmen C, Tsunekawa Y et al.Electrospinning of carbon nanofiber supported Fe/Co/Ni ternary alloy nanoparticles. Jl of Mats Prong Tech. 2010; 210(3): 451-455.
5. Huang ZM, Zhang YZ et al. A review on polymer nanofibers by electrospinning and their applications in nanocomposites. Composites science and technology. 2003; 63(15): 2223-2253.
6. Barnes CP, Sell SA et al. Nanofiber technology: designing the next generation of tissue engineering scaffolds. Advanced drug delivery reviews. 2007; 59(14): 1413-1433.
7. Pillay V, Dott C et al. A review of the effect of processing variables on the fabrication of electrospun nanofibers for drug delivery applications. J of Nanomaterials 2013.
8. Falde EJ, Freedman JD et al. Layered superhydrophobic meshes for controlled drug release. J of Controlled Release. 2015; 214: 23-29.
9. Owens Jr RC, Shorr AF .Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies.American J of Health-System Pharmacy. 2009; 66.
10. Bratzler R, Petersen D.Nucleic acids for the prevention and treatment of sexually transmitted diseases, Google Patents. 2001.
11. Chou SF, Carson D et al.Current strategies for sustaining drug release from electrospun nanofibers. J of Controlled Release. 2015; 220: 584-591.
12. Nagahama K, Ueda Y et al. Biodegradable shape-memory polymers exhibiting sharp thermal transitions and controlled drug release. Biomacromolecules. 2009; 10(7): 1789-1794.
13. Goldberg M, Langer R et al. Nanostructured materials for applications in drug delivery and tissue engineering.J of Biomaterials Science, Polymer Edition. 2007; 18(3): 241-268.
14. Vroman I, Tighzert L.Biodegradable polymers. Materials. 2009; 2(2): 307-344.

15. Li WJ, Mauck RL et al. Electrospun nanofibrous scaffolds: production, characterization, and applications for tissue engineering and drug delivery. J of Biomedical Nanotechnology. 2005; 1(3): 259-275.
16. Martin, A, Reis R et al. Electrospinning: processing technique for tissue engineering scaffolding." Int Mat Rev. 2008; 53(5): 257-274.
17. Frank SA. The design of natural and artificial adaptive systems. Adaptation. 1996; 451-505.
18. Shin YM, Kim KS et al. Modulation of Spreading, Proliferation and Differentiation of Human Mesenchymal Stem Cells on Gelatin-Immobilized Poly (l-lactide-co-ϵ-caprolactone) Substrates. Biomacromolecules. 2008; 9(7): 1772-1781.
19. Astrom BT. Manufacturing of polymer composites, CRC Press. 1997.
20. Subbiah T, Bhat G et al. Electrospinning of nanofibers. J of Applied Polymer Science. 2005; 96(2): 557-569.
21. Meinel AJ, Germershaus O et al.Electrospun matrices for localized drug delivery: current technologies and selected biomedical applications. Eur J of Pharmaceutics and Biopharmaceutics. 2012; 81(1): 1-13.
22. Bock N, Dargaville TR et al.Electrospraying of polymers with therapeutic molecules: state of the art. Progress in polymer science. 2012; 37(11): 1510-1551.
23. Sridhar R, Ravanan S et al. Curcumin-and natural extract-loaded nanofibres for potential treatment of lung and breast cancer: in vitro efficacy evaluation. J of Biomaterials Science, Polymer Edition. 2014; 25(10): 985-998.
24. Sheikh F, Kanjwal MA et al. A simple approach for synthesis, characterization and bioactivity of bovine bones to fabricate the polyurethane nanofiber containing hydroxyapatite nanoparticles.EXPRESS polymer letters. 2012; 6(1).
25. Jaffe M. Fiber Science—The Next Generation. 2005.
26. Gaucher G., Satturwar P et al.Polymeric micelles for oral drug delivery.Euro j of pharmaceutics and biopharmaceutics. 2010; 76(2): 147-158.
27. Sinha V, Bansal K et al. (2004). Poly-ϵ-caprolactone microspheres and nanospheres: an overview. Int j of pharmaceutics. 2004; 278(1): 1-23.
28. Beachley V,Wen X. Polymer nanofibrous structures: Fabrication, biofunctionalization, and cell interactions. Progress in polymer science. 2010; 35(7): 868-892.
29. Chiu JB, Luu YK et al. Electrospun nanofibrous scaffolds for biomedical applications. J of Biomedical Nanotechnology. 2005; 1(2): 115-132.

30. Goonoo N, Bhaw-Luximon A et al. Drug loading and release from electrospun biodegradable nanofibers. J of biomedical nanotechnology. 2014; 10(9): 2173-2199.
31. Takahashi H, Letourneur D et al. Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromolecules. 2007; 8(11): 3281-3293.
32. Aziz G, Geyter NDe et al. Incorporation of Primary Amines via Plasma Technology on Biomaterials.2015
33. Ito H.Chemical amplification resists for microlithography. Microlithography· Molecular Imprinting, Springer. 2005; 37-245.
34. Duschak V. Synthetic Biology: Computational Modeling Bridging the Gap between In Vitro and In Vivo Reactions. Current Synthetic and Systems Biology 2015.
35. Saraf A, Baggett LS et al.Regulated non-viral gene delivery from coaxial electrospun fiber mesh scaffolds. J of Controlled Release. 2010; 143(1): 95-103.
36. Liao IC, Chen S et al. Sustained viral gene delivery through core-shell fibers. Jof Cont Rel. 2009; 139(1): 48-55.
37. Zamani M, Prabhakaran MP et al.Advances in drug delivery via electrospun and electrosprayed nanomaterials. Int J Nanomedicine. 2013; 8(1): 2997-3017.
38. Tiwari SK, Tzezana R et al. Optimizing partition-controlled drug release from electrospun core–shell fibers. International journal of pharmaceutics. 2010; 392(1): 209-217.
39. Yoshida M, Langer R et al.From advanced biomedical coatings to multi-functionalized biomaterials. Journal of Macromolecular Science, Part C: Polymer Reviews. 2006; 46(4): 347-375.
40. Joung YK, Bae JW et al. Controlled release of heparin-binding growth factors using heparin-containing particulate systems for tissue regeneration.Expert opinion on drug delivery. 2008; 5(11): 1173-1184.
41. Wang Z, Sun B et al. Functionalization of electrospun poly (ε-caprolactone) scaffold with heparin and vascular endothelial growth factors for potential application as vascular grafts. J of Bioactive and Compatible Polymers. 2013; 28(2): 154-166.
42. Xu X, Yang L et al.Ultrafine medicated fibers electrospun from W/O emulsions. J of Cont Rel. 2005; 108(1): 33-42.
43. Xie J, Wang CH. Electrospun micro-and nanofibers for sustained delivery of paclitaxel to treat C6 glioma in vitro. Pharmaceutical research. 2006; 23(8): 1817-1826.

44. Verreck G, Chun I et al.Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning.Pharmaceutical research. 2003; 20(5): 810-817.
45. Piskin E, Bölgen N et al. Electrospun matrices made of poly (α-hydroxy acids) for medical use. 2007.
46. Zhang JJ, Liu J et al.Crosslinked Electrospun UPM/PHBV/PVP Fibers for Sustained Drug Release. Materials Science Forum, Trans Tech Publ. 2009.
47. Hansen CM. Hansen solubility parameters: a user's handbook, CRC press. 2007.
48. Ball C, Woodrow KA et al. Electrospun fibers for microbicide drug delivery.Drug Delivery and Development of Anti-HIV Microbicides:. 2014; 459-507.
49. Kim K, Luu YK et al.Incorporation and controlled release of a hydrophilic antibiotic using poly (lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J of Cont Rel. 2004; 98(1): 47-56.
50. Wang C,Yan KW et al.Biodegradable core/shell fibers by coaxial electrospinning: processing, fiber characterization and its application in sustained drug release. Macromolecules. 2010; 43(15): 6389-6397.
51. Luong-Van E, Grøndahl L et al.Controlled release of heparin from poly (ε-caprolactone) electrospun fibers. Biomaterials. 2006; 27(9): 2042-2050.
52. Zamani, M, Morshed M et al. Controlled release of metronidazole benzoate from poly ε-caprolactone electrospun nanofibers for periodontal diseases. Euro J of Pharmaceutics and Biopharmaceutics. 2010; 75(2): 179-185.
53. Cui W, Li X et al.Investigation of drug release and matrix degradation of electrospun poly (DL-lactide) fibers with paracetanol inoculation." Biomacromolecules. 2006; 7(5): 1623-1629.
54. Buschle-Diller G, Cooper J et al.Release of antibiotics from electrospun bicomponent fibers. Cellulose. 2007; 14(6): 553-562.
55. Chew SY, Wen J et al. Sustained release of proteins from electrospun biodegradable fibers. Biomacromolecules. 2005; 6(4): 2017-2024.
56. Ranganath SH, Wang CH. Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials. 2008; 29(20): 2996-3003.
57. Xie Z, Buschle-Diller G.Electrospun poly (D, L-lactide) fibers for drug delivery: The influence of cosolvent and the mechanism of drug release. J of applied polymer science. 2010; 115(1): 1-8.

58. Taepaiboon P, Rungsardthong U et al. Drug-loaded electrospun mats of poly (vinyl alcohol) fibres and their release characteristics of four model drugs. Nanotechnology. 2006; 17(9): 2317.
59. Yu DG, Shen XX et al. Oral fast-dissolving drug delivery membranes prepared from electrospun polyvinylpyrrolidone ultrafine fibers.Nanotechnology. 2009; 20(5): 055104.